Medical Device Network on MSN
Valar Labs hits US first with breakthrough designation for AI bladder cancer test
Valar Labs’ Vesta Bladder Risk Stratify Dx generates risk assessments for bladder cancer patients by analysing stained ...
The assay delivers a risk score that can help clinicians to tailor treatment intensity to a patient's risk of disease progression.
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...
After decades of limited options, a groundbreaking FDA-approved treatment is opening new doors for people with certain types of bladder cancer. Supported by Johnson & Johnson Bill is a real patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results